Core Insights - The AAPEX and SEMA exhibitions are showcasing the latest advancements in the automotive industry, particularly in smart technology, data utilization, and the transition to new energy sources [1][2] Group 1: Technology and Innovation - The widespread application of artificial intelligence and data analytics is a highlight of the exhibitions, indicating a shift in the automotive aftermarket towards digital upgrades driven by data [1] - Several exhibitors presented applications based on AI and big data for repair diagnostics, inventory forecasting, customer management, and supply chain optimization, aimed at enhancing operational efficiency and market responsiveness for parts suppliers and service providers [1] Group 2: Industry Trends - The exhibitions feature discussions on the application of AI in the automotive sector, including innovations in collision repair, calibration of advanced driver-assistance systems, intelligent inspection, and improvements in after-sales service efficiency [1] - New energy and future power systems are significant focal points, with multiple automakers showcasing modified vehicles powered by clean energy sources such as electricity and hydrogen, reflecting the industry's latest explorations in energy conservation and performance innovation [1]

Group 1 - The stock price of Tigermed (300347)(03347) increased by over 6%, reaching 47.98 HKD with a trading volume of 62.54 million HKD [1] - Citic Securities reported that Tigermed is enhancing its global presence and service capabilities, with significant teams in regions such as the US, Europe, Middle East, Africa, Japan, and South Korea [1] - In the first half of the year, the company's domestic main business revenue was 1.638 billion CNY, a decrease of 10.1% year-on-year, while overseas main business revenue was 1.541 billion CNY, an increase of 4.6% year-on-year [1] Group 2 - The growth in overseas revenue is attributed to the company's continued global expansion and service capabilities, accelerating its internationalization process [1] - The overseas clinical business maintained rapid growth, with an increase in revenue from clinical trial technical services [1] - The company announced the acquisition of Japanese CRO Micron in July 2025, which will enhance its local team in Japan and expand its client coverage in the Asia-Pacific region [1] Group 3 - The overseas clinical operations business showed a rapid growth trend, particularly in North America, with significant new order contributions expected in the second half of the year [2] - The clinical registration business experienced a notable recovery, with revenue growth exceeding 20% year-on-year, driven by increased demand for IND-related services both domestically and internationally [2] - The company established a data governance team in the first half of the year, launching multiple digital products to enhance digital management and integrating AI technology to improve digital capabilities [2]